Clinical trial
A Phase 2 Multicentre, Open-label Study to Evaluate the Efficacy, Safety and Tolerability, and Pharmacokinetics of 14 -28 Days Telacebec Treatment in Adult Participants With Buruli Ulcer.
NCT06481163 is registered in ClinicalTrials.gov with Barwon Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicentre, Open-label Study to Evaluate the Efficacy, Safety and Tolerability, and Pharmacokinetics of 14 -28 Days Telacebec Treatment in Adult Participants With Buruli Ulcer.
- Lead sponsor
- Barwon Health
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 9, 2024
- Completion date
- January 31, 2028
- Enrollment
- 200 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.